Enorama Pharma (Sweden) Market Value
| ERMA Stock | SEK 3.61 0.15 3.99% |
| Symbol | Enorama |
Enorama Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Enorama Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Enorama Pharma.
| 10/04/2023 |
| 11/27/2024 |
If you would invest 0.00 in Enorama Pharma on October 4, 2023 and sell it all today you would earn a total of 0.00 from holding Enorama Pharma AB or generate 0.0% return on investment in Enorama Pharma over 420 days. Enorama Pharma is related to or competes with Cantargia, Enzymatica Publ, Lidds AB, BioArctic, and Doxa AB. Enorama Pharma AB , a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven ... More
Enorama Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Enorama Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Enorama Pharma AB upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 27.06 | |||
| Value At Risk | (8.91) | |||
| Potential Upside | 10.4 |
Enorama Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enorama Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Enorama Pharma's standard deviation. In reality, there are many statistical measures that can use Enorama Pharma historical prices to predict the future Enorama Pharma's volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.37) | |||
| Total Risk Alpha | (1.26) | |||
| Treynor Ratio | 1.98 |
Enorama Pharma AB Backtested Returns
Enorama Pharma AB secures Sharpe Ratio (or Efficiency) of -0.0676, which denotes the company had a -0.0676% return per unit of risk over the last 3 months. Enorama Pharma AB exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Enorama Pharma's Mean Deviation of 4.16, standard deviation of 5.51, and Variance of 30.33 to check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.2, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Enorama Pharma are expected to decrease at a much lower rate. During the bear market, Enorama Pharma is likely to outperform the market. At this point, Enorama Pharma AB has a negative expected return of -0.36%. Please make sure to confirm Enorama Pharma's total risk alpha, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to decide if Enorama Pharma AB performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.40 |
Average predictability
Enorama Pharma AB has average predictability. Overlapping area represents the amount of predictability between Enorama Pharma time series from 4th of October 2023 to 1st of May 2024 and 1st of May 2024 to 27th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Enorama Pharma AB price movement. The serial correlation of 0.4 indicates that just about 40.0% of current Enorama Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.4 | |
| Spearman Rank Test | -0.35 | |
| Residual Average | 0.0 | |
| Price Variance | 1.41 |
Enorama Pharma AB lagged returns against current returns
Autocorrelation, which is Enorama Pharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Enorama Pharma's stock expected returns. We can calculate the autocorrelation of Enorama Pharma returns to help us make a trade decision. For example, suppose you find that Enorama Pharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Enorama Pharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Enorama Pharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Enorama Pharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Enorama Pharma stock over time.
Current vs Lagged Prices |
| Timeline |
Enorama Pharma Lagged Returns
When evaluating Enorama Pharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Enorama Pharma stock have on its future price. Enorama Pharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Enorama Pharma autocorrelation shows the relationship between Enorama Pharma stock current value and its past values and can show if there is a momentum factor associated with investing in Enorama Pharma AB.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Enorama Stock Analysis
When running Enorama Pharma's price analysis, check to measure Enorama Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enorama Pharma is operating at the current time. Most of Enorama Pharma's value examination focuses on studying past and present price action to predict the probability of Enorama Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enorama Pharma's price. Additionally, you may evaluate how the addition of Enorama Pharma to your portfolios can decrease your overall portfolio volatility.